Diligent Pharma is a technology company.
Diligent Pharma has raised $8.0M across 1 funding round.
Diligent Pharma has raised $8.0M in total across 1 funding round.
Diligent Pharma is a technology platform specializing in vendor qualification and risk management for the clinical trial industry, connecting sponsors (pharma and biotech companies) with service providers like CROs and vendors.[1][2][3] It solves the problem of slow, redundant vendor discovery, qualification, and oversight by centralizing data such as RFIs, audit reports, and risk scores, reducing timelines from months to days while ensuring regulatory compliance like GCP standards and FDA acceptance.[1][3][6] The platform drives faster study start-ups, higher efficiency, and lower risk, serving pharmaceutical sponsors, biotech firms, and vendors globally from its base in Princeton, New Jersey.[1][2]
Founded in 2018, Diligent Pharma has gained recognition as a Challenger in CB Insights' clinical trial regulatory solutions landscape alongside leaders like Veeva Systems and Medidata, backed by investors including FCA Venture Partners and pharma executives.[1] Its growth momentum stems from a proven model validated in FDA inspections and successful NDAs/BLAs, positioning it as a key enabler for life-saving treatments reaching patients faster.[6]
Diligent Pharma was founded in 2018 in Princeton, New Jersey, by Patty Leuchten, who previously established The Avoca Group, a consulting firm in clinical trial quality and risk management.[1][2] Leuchten's background at the intersection of clinical trial quality, GCP standards, and digital innovation inspired the platform's creation to address inefficiencies in vendor selection and qualification.[1][2] The idea emerged from recognizing redundancies in traditional processes—where sponsors repeatedly audit the same vendors—leading to a centralized database model that harnesses data for speed and compliance.[1][6]
Early traction came from individual investors like pharmaceutical executives and venture support from FCA Venture Partners, which backed the vision of centralizing qualification practices.[1] Pivotal moments include FDA review and acceptance of the model during inspections, with no compliance issues reported, and clients successfully using it for drug approvals, solidifying its credibility.[6]
Diligent Pharma stands out in the clinical trial ecosystem through technology simplified by deep expertise:
These features combine digital efficiency with hands-on quality assurance, differentiating from fragmented tools.[2][3]
Diligent Pharma rides the trend of digital transformation in clinical trials, where regulatory complexity and vendor fragmentation slow drug development amid rising trial costs and demands for speed.[1][6] Its timing aligns with post-pandemic shifts toward efficient, compliant tech—centralized data models address market forces like FDA emphasis on risk-based quality management and the need for faster study start-ups in a $50B+ clinical services market.[1][6]
By enabling outsourcing/augmentation for small-to-large sponsors, it influences the ecosystem through credible, shared qualification data, reducing redundancy and supporting scalable partnerships.[6] As a Challenger in CB Insights' matrix, it complements giants like Veeva, fostering innovation in digital health infrastructure for pharma/biotech.[1]
Diligent Pharma is poised for expansion as AI-driven insights and real-time risk tools enhance its platform, capitalizing on growing clinical trial digitization and regulatory evolution.[1][2] Trends like decentralized trials and stricter compliance will amplify demand for its centralized model, potentially through partnerships with CROs or integrations with trial management systems.[3][6] Its influence may evolve from niche qualifier to ecosystem standard, accelerating therapies while maintaining FDA-validated rigor—tying back to its core mission of faster, higher-quality paths to patients.[2][6]
Diligent Pharma has raised $8.0M in total across 1 funding round.
Diligent Pharma's investors include Asymmetric Capital Partners, Karim Faris, Okta Ventures, Point Judith Capital, Sandwith Ventures, Scale Asia Ventures, Underdog Labs, George Kurtz, Howard Love.
Diligent Pharma has raised $8.0M across 1 funding round. Most recently, it raised $8.0M Series A in May 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2023 | $8.0M Series A | Asymmetric Capital Partners, Karim Faris, Okta Ventures, Point Judith Capital, Sandwith Ventures, Scale Asia Ventures, Underdog Labs, George Kurtz, Howard Love |